Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(166 productos)
- Bcr-Abl(117 productos)
- EGFR(551 productos)
- FAK(72 productos)
- FLT(88 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(176 productos)
- JAK(243 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(51 productos)
- VDA(2 productos)
- VEGFR(236 productos)
Mostrar 6 subcategorías más
Se han encontrado 2269 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Larixol
CAS:Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical forFórmula:C20H34O2Pureza:98%Forma y color:SolidPeso molecular:306.48FM-479
CAS:FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.
Fórmula:C25H26N6O2Pureza:98%Forma y color:SolidPeso molecular:442.5232′-Thioadenosine
CAS:2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM againstFórmula:C10H13N5O3SPureza:98%Forma y color:SolidPeso molecular:283.31TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Fórmula:C17H11ClF2N4O2Forma y color:SolidPeso molecular:376.74PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Fórmula:C22H21ClN6O2Forma y color:SolidPeso molecular:436.89TL02-59
CAS:TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.Fórmula:C32H34F3N5O4Pureza:98.77%Forma y color:SolidPeso molecular:609.64Ref: TM-T13186
1mg49,00€2mg62,00€5mg93,00€10mg133,00€25mg260,00€50mg401,00€100mg557,00€200mg790,00€1mL*10mM (DMSO)111,00€AKB-6899
CAS:AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treatedFórmula:C14H11FN2O4Pureza:97.87%Forma y color:SolidPeso molecular:290.25JGK-068S
CAS:Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35TYRA-300
CAS:TYRA-300 is an oral and selective FGFR3 inhibito, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.Fórmula:C25H24Cl2N6O3SPureza:99.66%Forma y color:SolidPeso molecular:559.47Ref: TM-T88841
1mg404,00€5mg735,00€10mg999,00€25mg1.588,00€50mg2.147,00€100mg2.902,00€1mL*10mM (DMSO)904,00€VEGFR-2-IN-9
CAS:VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.Fórmula:C23H25N3O3Pureza:97.19%Forma y color:SolidPeso molecular:391.46JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Fórmula:C21H19N7O2S2Pureza:98%Forma y color:SolidPeso molecular:465.55Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Fórmula:C18H21N5O3Pureza:99.85%Forma y color:SolidPeso molecular:355.39Ref: TM-T78207
1mg50,00€5mg104,00€10mg167,00€25mg340,00€50mg505,00€100mg712,00€200mg1.009,00€1mL*10mM (DMSO)114,00€Ruxolitinib sulfate
CAS:Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.Fórmula:C17H20N6O4SForma y color:SolidPeso molecular:404.45Famitinib malate
CAS:Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.Fórmula:C27H33FN4O7Forma y color:SolidPeso molecular:544.57Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Fórmula:C18H21F2N7OPureza:99.82%Forma y color:SolidPeso molecular:389.4Ref: TM-TQ0010
1mg34,00€2mg46,00€5mg66,00€10mg99,00€25mg205,00€50mg371,00€100mg595,00€200mg833,00€1mL*10mM (DMSO)73,00€HDAC-IN-63
CAS:HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.Fórmula:C25H26Cl2N6O3Forma y color:SolidPeso molecular:529.42Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Fórmula:C42H51N9O5Forma y color:SolidPeso molecular:761.91Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Fórmula:C21H33F3N6O11Pureza:98%Forma y color:SolidPeso molecular:602.521OTS447
CAS:OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .Fórmula:C27H32ClN3O2Pureza:98.78%Forma y color:SolidPeso molecular:466.02FLT3-IN-14
CAS:FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.Fórmula:C25H24N6O2SForma y color:SolidPeso molecular:472.56
